GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

The UK-based consumer healthcare company will be modernizing its facility along Brook Road, where it conducts R&D for such ...

The global antacids market is on track for substantial expansion, with projections indicating a rise from USD 6,971.2 million ...

MORE than a trillion dollars were wiped off some of the world’s biggest tech firms yesterday after markets were blindsided by ...

The Chalk River Nuclear Facility is cited as the largest supplier of medical radioisotopes in the world. (Chalk River was ...